FOXM1 Is a Therapeutic Target in High-Risk Multiple Myeloma

Clinical Lymphoma, Myeloma and Leukemia - United States
doi 10.1016/j.clml.2015.07.499
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

TRAF6 Activation in Multiple Myeloma: A Potential Therapeutic Target

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2012English

RSK2Ser227 at N-Terminal Kinase Domain Is a Potential Therapeutic Target for Multiple Myeloma

Molecular Cancer Therapeutics
Cancer ResearchOncology
2012English

Polo-Like Kinase 1 Is a Therapeutic Target in High-Risk Neuroblastoma

Clinical Cancer Research
Cancer ResearchOncology
2010English

CD26 Is a Potential Therapeutic Target by Humanized Monoclonal Antibody for the Treatment of Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2018English

EZH2 as a Therapeutic Target for Multiple Myeloma and Other Haematological Malignancies

Biomarker Research
BiochemistryMolecular MedicineClinical Biochemistry
2018English

Multiple Myeloma-Associated AL Amyloidosis: Is a Distinctive Therapeutic Approach Warranted?

Bone Marrow Transplantation
TransplantationHematology
2006English

TAK1 Is a Pivotal Therapeutic Target for Tumor Progression and Bone Destruction in Myeloma

Haematologica
Hematology
2020English

High-Risk Multiple Myeloma: Different Definitions, Different Outcomes?

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2014English

Overexpression of FoxM1 Offers a Promising Therapeutic Target in Diffuse Large B-Cell Lymphoma

Haematologica
Hematology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy